Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
INDUSTRY BRIEF: Healthcare stocks under pressure as national drug list expands
Many Hong Kong-listed drugmakers on Monday announced their products that were included in the 2025 edition of China’s National Reimbursement Drug List (NRDL), which was unveiled this week. The updated…
Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
BRIEF: Bao Pharma launches $128 million Hong Kong IPO
Shanghai Bao Pharma Co. Ltd. (2659.HK) launched its Hong Kong IPO on Tuesday, planning to sell 37.9 million shares at an offer price of HK$26.38 per share, raising up to…
CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
WuXi AppTec frees up money for Middle East push
The drugs services giant has stepped up sales of non-core Chinese assets to concentrate on its international expansion, with plans for a base in Saudi Arabia Key Takeaways: The company…
Recent Articles
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK
600196.SHG
WuXi AppTec frees up money for Middle East push
2359.HK
603259.SHG
